Biohaven Pharmaceutical Holding Co Ltd. Intellectual Property Contracts & Agreements
8 Contracts & Agreements
- License Agreements (8 contracts)
- Amendment to License Agreement, dated September 4, 2018, by and between Biohaven Therapeutics Ltd. and AstraZeneca AB (Filed With SEC on November 14, 2018)
- Amendment to License Agreement, dated March 9, 2018, by and between Biohaven Pharmaceutical Holding Company Ltd. and Bristol-Myers Squibb Company (Filed With SEC on August 14, 2018)
- EXCLUSIVE LICENSE AGREEMENT between Biohaven Pharmaceutical Holding Co. Ltd and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (Filed With SEC on April 24, 2017)
- THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125 (Filed With SEC on April 24, 2017)
- ZYDIS DEVELOPMENT AND LICENSE AGREEMENT (Riluzole) (Filed With SEC on April 24, 2017)
- EXCLUSIVE LICENSE AGREEMENT between Biohaven Pharmaceutical Holding Co. Ltd and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (Filed With SEC on April 7, 2017)
- THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125 (Filed With SEC on April 7, 2017)
- ZYDIS DEVELOPMENT AND LICENSE AGREEMENT (Riluzole) (Filed With SEC on April 7, 2017)
